ClinicalTrials.gg
WithdrawnNCT03325725Updated Jan 12, 2018

Intra-laryngeal Implant for Treatment of Chronic Aspirations

An interventional study of NewBreez LD intra-laryngeal implant in Aspiration Pneumonia and Tracheostomy Complication, sponsored by ProTiP Medical. Withdrawn at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-01-12.

Sponsored by ProTiP Medical · Not applicable, Interventional, and Device feasibility

Why this study was withdrawn
The Competent Authority did not give the authorization to start the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study evaluates the medical device Newbreez LD is designed to protect the lower airways from saliva, liquids and food aspirations in tracheotomized patients suffering from chronic aspirations that require specific care and may lead to complications, including inhalation pneumonia.

Read the detailed description

Patients suffering from swallowing disorders characterized by chronic aspirations (repeated episodes of aspirations defined as penetration of material - liquids, food, saliva, into the respiratory system due to a malfunctioning of the swallowing mechanism) are subject to pathologies and pulmonary insufficiencies. The risks of aspiration pneumonia or suffocation are significantly greater if the patient is not able to expectorate and thus engages the vital prognosis. There are several methods to treat chronic aspirations: the least invasive methods involve adopting postures and/or positions of the body during swallowing and adapting food textures; when these treatments are insufficient there is the need to recur to more advanced ones to protect the airways and keep the patient on a sufficient nutrition.

For these severe cases, heavier surgical methods can be also considered. These methods lead to important anatomical changes, with a variable degree of reversibility, up to irreversibility (eg total laryngectomy). Among surgical methods, there is also an implant of a tracheotomy cuffed cannula that allows patient to breathe through a hole in the trachea. The efficacy of this solution is highly controversial as reported by numerous studies and several adverse effects are reported on the tracheal duct.

Due to the interest of a prosthetic treatment and the disadvantages of the current methods and devices, PROTiP Medical has developed a closed intra-laryngeal implant: NewBreez LD. This device is innovative because its geometry has been optimized to conform totally to the anatomy of the larynx with the aim to ensure a sealing against saliva, liquids and food aspirations.

02

Conditions studied

  • Aspiration Pneumonia
  • Tracheostomy Complication

Browse trials for

Keywords

  • severe aspiration
03

In context

Pneumonia, Aspiration

73 studies on the registry are indexed under Pneumonia, Aspiration; 12 are open to participants now.

Browse Pneumonia, Aspiration studies →

Lead sponsor

ProTiP Medical is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Swallowing disorders characterized by chronic aspirations;
  • Tracheotomy performed, inter alia, in the management of swallowing disorders;
  • Aged over 18;
  • Willing and able to comply with the requirements of the study;
  • signed;
  • Affiliated patient or beneficiary of the social security system.

Exclusion criteria

Exclusion Criteria:

  • Do not implant in patients with incomplete cricoid cartilage (surgery or other);
  • Do not implant in patients with tracheotomy performed by cricothyroidectomy or between cricoid cartilage and the 1st tracheal ring;
  • Do not implant in patients with tracheal lumen in the 1st tracheal ring, the lateral and anteroposterior diameters of which are less than 11 mm;
  • Do not implant in patients with tight trismus;
  • Do not implant in subjects less than 18 years of age;
  • Do not implant in patients with bleeding disorders;
  • Do not implant in patients to general anesthesia.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    NewBreez LD Intra-laryngeal implant

    Device: NewBreez LD intra-laryngeal implant

Interventions

  • DeviceNewBreez LD intra-laryngeal implant

    NewBreez LD intra-laryngeal implantation

06

What researchers measure

Primary outcomes

  1. Sealing of the NewBreez LD: Protection of the lower airways will be assessed using the gold standard exam, videofluoroscopy (VFS)

    Protection of the lower airways will be assessed using the gold standard exam, videofluoroscopy (VFS)

    Time frame: 7 days

Other outcomes

  1. Stability of the NewBreez LD: Number of patients who kept the implant until the end of the study period.

    Number of patients who kept the implant until the end of the study period.

    Time frame: 30 days

  2. Safety of the NewBreez LD: Number of patient with adverse events will be assessed at each follow-up during the study period

    Number of patient with adverse events will be assessed at each follow-up during the study period

    Time frame: 2, 7, 30 days

07

Study locations

2 sites
  • CHU Strasbourg
    Strasbourg, 67000, France
  • CHU Toulouse
    Toulouse, 31000, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2018 to primary completion in Jan 2018, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2017
First posted
Oct 30, 2017
StartActual
Jan 9, 2018
Primary completionActual
Jan 9, 2018
CompletionActual
Jan 9, 2018
Last update
Jan 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03325725
Lead sponsor
ProTiP Medical
Responsible party
Sponsor
First posted
Oct 30, 2017
Start date
Jan 9, 2018
Primary completion
Jan 9, 2018
Completion
Jan 9, 2018
Last update
Jan 12, 2018

Study contacts

Christian Debry, Pr.
principal investigator · CHU Strasbourg

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion